Literature DB >> 18522492

Structural stabilization in tetrameric or polymeric hemoglobin determines its interaction with endogenous antioxidant scavenger pathways.

Paul W Buehler1, Florence Vallelian, Malgorzata G Mikolajczyk, Gabriele Schoedon, Thomas Schweizer, Abdu I Alayash, Dominik J Schaer.   

Abstract

Hemoglobin (Hb) released into the circulation during hemolysis and chemically modified Hb proposed for use as oxygen therapeutics exert toxic effects that are partially attributable to heme's oxidant activity. Native extracellular Hb is scavenged by haptoglobin (Hp) after alphabeta-subunit dimerization. In the absence of Hp, monocyte/macrophage cell-surface CD163 binds and clears Hb. We evaluated several chemically modified Hbs to establish the role of chemical cross-linking patterns and molecular sizes on binding and clearance by each pathway. We found that Hbs possessing beta-globin cross-linking, irrespective of polymerization, demonstrate increased Hp affinity compared with alpha-globin-stabilized Hbs. These data suggest that Hb alpha-subunit accessibility is critical for Hp binding in the absence of dimerization. beta-Globin chain cross-linked tetramers/polymers displayed strong polyvalent Hp binding with increased viscosity and formation of visible gel matrices. Modified Hb interaction with CD163 and cellular uptake demonstrated an inverse relation with molecular size, irrespective of alpha and beta cross-linking. These findings were confirmed by HO-1 induction and intracellular ferritin accumulation in CD163-expressing HEK293 cells. Based on these results, a rational and systematic approach to HBOC design may be used to optimize interaction with endogenous Hb clearance and detoxification pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522492     DOI: 10.1089/ars.2008.2028

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  11 in total

1.  Human Hp1-1 and Hp2-2 phenotype-specific haptoglobin therapeutics are both effective in vitro and in guinea pigs to attenuate hemoglobin toxicity.

Authors:  Miriam Lipiski; Jeremy W Deuel; Jin Hyen Baek; Wolfgang R Engelsberger; Paul W Buehler; Dominik J Schaer
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

2.  A new polyethyleneglycol-derivatized hemoglobin derivative with decreased oxygen affinity and limited toxicity.

Authors:  Oana Zolog; Augustin Mot; Florina Deac; Alina Roman; Eva Fischer-Fodor; Radu Silaghi-Dumitrescu
Journal:  Protein J       Date:  2011-01       Impact factor: 2.371

3.  Down selection of polymerized bovine hemoglobins for use as oxygen releasing therapeutics in a guinea pig model.

Authors:  Jin Hyen Baek; Yipin Zhou; David R Harris; Dominik J Schaer; Andre F Palmer; Paul W Buehler
Journal:  Toxicol Sci       Date:  2012-03-12       Impact factor: 4.849

Review 4.  Exploring Oxidative Reactions in Hemoglobin Variants Using Mass Spectrometry: Lessons for Engineering Oxidatively Stable Oxygen Therapeutics.

Authors:  Michael Brad Strader; Abdu I Alayash
Journal:  Antioxid Redox Signal       Date:  2016-10-20       Impact factor: 8.401

5.  Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs.

Authors:  Felicitas S Boretti; Paul W Buehler; Felice D'Agnillo; Katharina Kluge; Tony Glaus; Omer I Butt; Yiping Jia; Jeroen Goede; Claudia P Pereira; Marco Maggiorini; Gabriele Schoedon; Abdu I Alayash; Dominik J Schaer
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

Review 6.  Heme degradation and vascular injury.

Authors:  John D Belcher; Joan D Beckman; Gyorgy Balla; Jozsef Balla; Gregory Vercellotti
Journal:  Antioxid Redox Signal       Date:  2010-02       Impact factor: 8.401

Review 7.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

Review 8.  Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development.

Authors:  Dominik J Schaer; Francesca Vinchi; Giada Ingoglia; Emanuela Tolosano; Paul W Buehler
Journal:  Front Physiol       Date:  2014-10-28       Impact factor: 4.566

9.  Haptoglobin preferentially binds β but not α subunits cross-linked hemoglobin tetramers with minimal effects on ligand and redox reactions.

Authors:  Yiping Jia; Francine Wood; Paul W Buehler; Abdu I Alayash
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

10.  Chloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent.

Authors:  Christian A Schaer; Endre Laczko; Gabriele Schoedon; Dominik J Schaer; Florence Vallelian
Journal:  Oxid Med Cell Longev       Date:  2013-06-11       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.